International audienceBACKGROUND:Mucosal healing can be achieved with infliximab (IFX).AIM:To assess the impact of mucosal healing on long-term outcomes in patients with ulcerative colitis (UC) when treated with infliximab (IFX) beyond 1 year.METHODS:All consecutive adult patients with refractory UC receiving maintenance treatment with IFX in five French referral centres were analysed retrospectively. Only patients who had endoscopic evaluation between 6 and 52 weeks following IFX initiation were included. According to their Mayo endoscopic sub-score, patients were categorised into mucosal healing (sub-score: 0-1) and no mucosal healing (2-3). Outcome measures were colectomy and IFX failure defined by drug withdrawal due to secondary failur...
Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical trials in i...
International audienceBACKGROUND AND AIMS: Long-term benefits of combination therapy (combotherapy) ...
BACKGROUND: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free c...
International audienceBACKGROUND:Mucosal healing can be achieved with infliximab (IFX).AIM:To assess...
International audienceBackground: The long term efficacy of adalimumab in ulcerative colitis (UC) pa...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data...
BACKGROUND: Infliximab has been shown to be of benefit in the treatment of ulcerative colitis but lo...
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
Background: Real-life long-term data on infliximab treatment in ulcerative colitis are limited. Aim:...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Background: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free clini...
BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of corticosteroids...
Aim: To assess the endoscopic activity and Clinical activity after a one-year period of infliximab t...
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously bee...
Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical trials in i...
International audienceBACKGROUND AND AIMS: Long-term benefits of combination therapy (combotherapy) ...
BACKGROUND: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free c...
International audienceBACKGROUND:Mucosal healing can be achieved with infliximab (IFX).AIM:To assess...
International audienceBackground: The long term efficacy of adalimumab in ulcerative colitis (UC) pa...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data...
BACKGROUND: Infliximab has been shown to be of benefit in the treatment of ulcerative colitis but lo...
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
Background: Real-life long-term data on infliximab treatment in ulcerative colitis are limited. Aim:...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Background: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free clini...
BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of corticosteroids...
Aim: To assess the endoscopic activity and Clinical activity after a one-year period of infliximab t...
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously bee...
Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical trials in i...
International audienceBACKGROUND AND AIMS: Long-term benefits of combination therapy (combotherapy) ...
BACKGROUND: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free c...